TY - JOUR
T1 - Transurethral vaportrode electrovaporization of the prostate
T2 - Physical principles, technique, and results
AU - Narayan, Perinchery
AU - Tewari, Ashutosh
AU - Garzotto, Mark
AU - Parramore, Herman W.
AU - Schalow, Erica
AU - Starling, Jeff
AU - Jones, Talmadge
N1 - Funding Information:
*This work was supported by National Institutes of Health grant (ROlDK47517-01) and Department of Veterans Affairs Merit review grant awarded to P.N. From the University of Florida School of Medicine and Departments of Veterans Affairs Medical Center, Gainesville, Florida Reprint requests: Perinchery Narayan, M.D., Division of Urology, University of Florida, P.O. Box 100247, Gainesville, FL 32610 Submitted (Rapid Communication): October 30, 1995, accepted (with revisions): December 14, 1995
PY - 1996/4
Y1 - 1996/4
N2 - Objectives. This is a study to evaluate technique, efficacy, and safety of a new electrosurgical instrument (Vaportrode) in management of benign prostatic hyperplasia (BPH). Methods. Forty-two symptomatic BPH patients form the subject of this study. Preoperative and postoperative International Prostate Symptom Score (IPSS), peak flow rates (PFR), postvoid residual urine (PVR), operative details, and complications were recorded in each patient. Baseline, 1, 3, and 6 months follow-up data were used for analyses. Results. Results reveal that transurethral electrovaporization of the prostate (TUEVP) is a reasonable procedure to treat symptomatic BPH, and at 6 months, this procedure results in 68% reduction in IPSS, 128% improvement in PFR, and 58% reduction in PVR. Even in patients who are in retention prior to TUEVP, at 6 months the IPSS is 7.7, PFR is 20.4 cc/s, and PVR reduces to 130 cc. The procedure is well tolerated without any significant short-term complications. Conclusions. The results of this modality in improving the symptoms and PFR in symptomatic BPH patients in the short term appear promising. Advantages over transurethral resection (TUR) of the prostate and laser prostatectomy include familiarity of the transurethral route, lack of need for high-cost laser equipment and fibers, excellent intraoperative hemostasis, lack of bleeding or fluid absorption, and ability to cause a predictable TUR-like prostate defect at the end of the procedure. Further studies involving larger numbers of patients and longer follow-up are warranted to assess further the utility of this procedure.
AB - Objectives. This is a study to evaluate technique, efficacy, and safety of a new electrosurgical instrument (Vaportrode) in management of benign prostatic hyperplasia (BPH). Methods. Forty-two symptomatic BPH patients form the subject of this study. Preoperative and postoperative International Prostate Symptom Score (IPSS), peak flow rates (PFR), postvoid residual urine (PVR), operative details, and complications were recorded in each patient. Baseline, 1, 3, and 6 months follow-up data were used for analyses. Results. Results reveal that transurethral electrovaporization of the prostate (TUEVP) is a reasonable procedure to treat symptomatic BPH, and at 6 months, this procedure results in 68% reduction in IPSS, 128% improvement in PFR, and 58% reduction in PVR. Even in patients who are in retention prior to TUEVP, at 6 months the IPSS is 7.7, PFR is 20.4 cc/s, and PVR reduces to 130 cc. The procedure is well tolerated without any significant short-term complications. Conclusions. The results of this modality in improving the symptoms and PFR in symptomatic BPH patients in the short term appear promising. Advantages over transurethral resection (TUR) of the prostate and laser prostatectomy include familiarity of the transurethral route, lack of need for high-cost laser equipment and fibers, excellent intraoperative hemostasis, lack of bleeding or fluid absorption, and ability to cause a predictable TUR-like prostate defect at the end of the procedure. Further studies involving larger numbers of patients and longer follow-up are warranted to assess further the utility of this procedure.
UR - http://www.scopus.com/inward/record.url?scp=0030004235&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030004235&partnerID=8YFLogxK
U2 - 10.1016/S0090-4295(99)80485-3
DO - 10.1016/S0090-4295(99)80485-3
M3 - Article
C2 - 8638358
AN - SCOPUS:0030004235
SN - 0090-4295
VL - 47
SP - 505
EP - 510
JO - Urology
JF - Urology
IS - 4
ER -